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Introduction

81
Aspergillus fumigatus is a leading cause of pulmonary fungal infections in 
100
Here, we use a well-validated in vitro model of the human alveolus (9) to describe the 101 pharmacodynamics of itraconazole against both wild-type and resistant strains of Aspergillus 102 fumigatus. This model has enabled us to explore some potential advantages of innovative
MATERIALS AND METHODS
111
Isolates of Aspergillus fumigatus and In Vitro Susceptibility Testing.
112
The initial pharmacodynamic experiments were performed using a green fluorescent 113 protein (GFP) transformant of Aspergillus fumigatus as previously described (9, 12, 13 
125
In vitro Model of the Human Alveolus.
126
A previously described cell culture model of the human alveolus was used to investigate 
133
(pulmonary vasculature). Itraconazole was administered into the endothelial compartment (to 134 mimic systemic drug administration) or within the alveolar compartment to mimic aerosolized 135 therapy. Antifungal activity was estimated using galactomannan, as previously described (9).
136
Evidence from both laboratory animal models and clinical settings suggest that concentrations 137 of galactomannan are inextricably related to the pathogenesis of invasive pulmonary 138 aspergillosis and the ultimate prognosis (10). Sampling from the in vitro model was destructive
139
(i.e. each insert contributed a single terminal sample meaning that sampling did not have an
6
The inoculum for each strain was prepared as previously described (9, 12, 13 
178
progressing to 30% over 4 minutes and flow rate of 1 mL/min. Itraconazole and the internal 179 standard were detected using UV 254 nm; they eluted after 4.6 and 2.9 minutes, respectively.
180
The CV% was <6% over the concentration range 0.125 -8 mg/L. The limit of detection was 0.125 181 mg/L. The intra and inter-day variation was <7%. 
211
The combination of systemically administered 5FC and airway administration of 212 itraconazole against L98 was studied. The combination matrix was designed with prior 213 information related to the exposure-response relationships for each modality alone (obtained 214 from the experiments described above). Itraconazole was administered to the alveolar 215 compartment to achieve initial concentrations of 0-8 mg/L. Simultaneously, 5FC was 216 administered to the endothelial compartment to achieve concentrations 0-120 mg/L.
217
Combinations of these regimens were then studied.
219
Data Analysis and Mathematical Modeling
220
The pharmacodynamic data were modeled using an inhibitory sigmoid Emax model that 
229
The combination of the airway administration of itraconazole and systemic 5FC was 230 modeled using the Greco model, which is in turn based upon the concept of Loewe additivity. 
276
respectively. There was a sub-maximal decline in galactomannan in the alveolar compartment.
277
The airway administration of itraconazole resulted in comparable exposure response 278 relationships (Figure 3 ). In this case the E 50 (95% confidence interval) for the alveolar and 
292
Pharmacodynamics of Systemically Administered 5FC
293
The exposure response relationships in the alveolar and endothelial compartments with 294 flucytosine were defined using an initial concentration of 0-120 mg/L. 5FC induced relatively 295 languid exposure response relationships in both compartments ( Figure 6 ). The E 50 (95% 
358
The achievement of high concentrations in this sub-compartment may far exceed the MIC and
359
exert at least some antifungal activity. A similar concept has been recently described for 360 posaconazole (2).
361
The observation of at least some, albeit sub-maximal antifungal effect following 
375
While not synergistic, the additive interaction may still be clinically beneficial to help secure a 
382
There are a number of limitations of this study. 
